Bionovo Launches Pharmacokinetics Trial Of Its Lead Menopause Drug Candidate, MF101

... Bionovo, Inc. (OTC Bulletin Board: BNVI) has begun enrollment for its single ascending dose pharmacokinetics clinical trial to further evaluate the company's lead drug candidate, MF101, designed to treat the symptoms of menopause. The clinical trial will take place at the University of Colorado at Denver and Health Sciences Center, with Dr. Thomas Henthorn as lead investigator. [click link for full article] ...